NP-12 // NP031112 // Zentylor // Tideglusib .
This study is ongoing, but not recruiting participants.
First Received: January 13, 2010 Last Updated: October 7, 2010
Brief title Safety, Tolerability, and Efficacy of Two Different Oral Doses of NP031112 Versus Placebo in the Treatment of Patients With Mild-to-Moderate Progressive Supranuclear Palsy
The purpose of this study is to determine wether NP031112 is safe and effective in the treatment of mild to moderate Progressive Supranuclear Palsy
Enrollment: 146
Study Start Date: December 2009
Estimated Study Completion Date: November 2011
Estimated Primary Completion Date: September 2011 (Final data collection date for primary outcome measure)
Administrative Data
Organization name Noscira SA
Organization study ID NP031112-08B02
Sponsor Noscira SA
Collaborator i3 Research
Health Authority United States: Food and Drug Administration
Health Authority United Kingdom: Medicines and Healthcare Products Regulatory Agency
Health Authority Spain: Spanish Agency of Medicines
Health Authority Germany: Federal Institute for Drugs and Medical Devices
...
